Dengue, Phase 1
Conditions
Keywords
Dengue
Brief summary
This Phase 1 study to evaluate the safety of a single dose of Dengushield (dengue monoclonal antibody) in healthy adults.
Detailed description
This Phase 1 study will evaluate the safety and tolerability of a single dose of Dengushield (dengue monoclonal antibody) in healthy adults in a dose-escalating study design. In addition, pharmacokinetics will also be studied.
Interventions
BIOLOGICALDengushield 1 mg/kg (Cohort 1) intravenous
Participants will be administered Dengushield 1 mg/kg as slow intravenous injection.
BIOLOGICALDengushield 3 mg/kg (Cohort 2) intravenous
Participants will be administered Dengushield 3 mg/kg as slow intravenous infusion.
BIOLOGICALPlacebo 3 mg/kg (Cohort 2) intravenous
Participants will be administered Placebo 3 mg/kg as slow intravenous infusion.
BIOLOGICALDengushield 7 mg/kg (Cohort 3) intravenous
Participants will be administered Dengushield 7 mg/kg as slow intravenous infusion.
BIOLOGICALPlacebo 7 mg/kg (Cohort 3) intravenous
Participants will be administered Placebo 7 mg/kg as slow intravenous infusion.
BIOLOGICALDengushield 12 mg/kg (Cohort 4) intravenous
Participants will be administered Dengushield 12 mg/kg as slow intravenous infusion.
BIOLOGICALPlacebo 12 mg/kg (Cohort 4) intravenous
Participants will be administered Placebo 12 mg/kg as slow intravenous infusion.
Sponsors
PPD Development, LP
Serum Institute of India Pvt. Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Masking description
For the Cohort 1 (Initial Safety Cohort), no placebo control will be used and hence, blinding is not applicable.For remaining cohorts, both participant and investigator will be unaware of treatment allocation as well as the laboratories analyzing the biochemistry and hematology parameters, pharmacokinetic and immunogenicity (ADA) samples will be blinded to treatment allocation. The drug administrator will be unblinded who will prepare and administer the study drugs. The 7 day safety data for each cohort will be reviewed by group-wise unblinding. Individual level unblinding will be done only in cases of suspected serious adverse reactions as per the judgement of investigator or medical monitor / sponsor representative.
Intervention model description
This is a Phase 1, randomized, partially-blind (observer-blind), placebo controlled, single dose ascending study in healthy adults. For the Cohort 1 (Initial Safety Cohort), no placebo control will be used and hence, blinding is not applicable. There will be 4 dose levels. The proposed doses to be studied are; 1 mg/kg, 3 mg/kg, 12 mg/kg and 25 mg/kg. Total of 40 participants will be dosed and followed till Day 84 from dosing.
Eligibility
Sex/Gender
ALL
Age
18 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
1. Healthy adults aged 18-45 years, men, or women. 2. Negative Dengue NS1 at screening indicating no current dengue infection 3. Seronegative for dengue IgG 4. Participants who are willing to comply with the requirements of the study protocol and attend scheduled visit. 5. Participants who give written informed consent. 6. Participants having laboratory parameters within normal range 7. Participants with Body Mass Index (BMI) between 18 to 30 (both inclusive) 8. Satisfactory baseline medical assessment as assessed by physical examination and normal laboratory values or minor variations that is acceptable for study entry.
Exclusion criteria
1. Presence of acute infection in the preceding 14 days or presence of a temperature ≥ 38.0°C, or acute symptoms of infection greater than of mild severity on the scheduled date of first dosing 2. History or presence of clinically significant cardiovascular, respiratory, hepatic, renal, gastrointestinal, neuropsychiatric, autoimmune, dermatologic or immunosuppressive disorders. 3. Evidence of any other significant active haematological disease, or having donated \> 450 mL of blood within the past three months. 4. Evidence or history of substance abuse including alcohol, or previous substance abuse within the last year. 5. Participation or planned participation in a study involving the administration of an investigational compound within the past one month or during this study period. 6. Planned administration of any vaccine not foreseen by the study protocol 4 weeks before and after dosing except for influenza vaccination. 7. Receipt of immunoglobulins and/or any blood products within 9 months of study enrolment or planned administration of any of these products during the study period. 8. Laboratory confirmed infection with hepatitis B virus (HBsAg positive), hepatitis C virus (anti-HCV positive) or human immunodeficiency virus (HIV positive) at screening. 9. History of allergic disease, allergic reactions or known hypersensitivity to any component of the study product (Mild non-medication allergies allowed). 10. Known bleeding disorders. 11. Women who are pregnant, breast-feeding, or considering becoming pregnant. 12. Any condition that, in the opinion of the investigator, would complicate or compromise the study or well-being of the participant.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The proportion of participants with post-injection/ infusion adverse events (AEs) including hypersensitivity reaction, anaphylactic reaction and other AEs occurring within 4 hours of the start of dosing | 4 hours post administration of drug | Safety monitoring for 4 hours |
| The proportion of participants with AEs, discontinuations due to AEs, and serious adverse events (SAEs) | 84 days | Safety |
| Proportion of participants with clinically significant abnormal safety laboratory (hematology and chemistry parameters) findings | 28 days | Safety |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| AUC from time 0 to infinity of Dengushield | 84 days | Area under curve of Dengushield from time 0 to infinity (AUC0-infinity) |
| AUC from time 0 to 84 days of Dengushield | 84 days | Area under curve of Dengushield from time 0 to 84 days (AUC0-84d) |
| Half life of Dengushield - t1/2 | 84 days | Half life of Dengushield |
| Time to maximum serum concentration of Dengushield - Tmax | 84 days | Time to maximum serum concentration of Dengushield - Tmax |
| Clearance of dengushield | 84 days | Clearance of dengushield |
| Elimination rate constant of dengushield | 84 days | Elimination rate constant of dengushield |
| Volume of distribution of Dengushield | 84 days | Volume of distribution of Dengushield |
| Presence or absence of anti-Dengushield antibody in sera samples | 84 days | Anti-Dengushield antibodies will be checked in sera samples. |
| Maximum serum concentration of dengushield - Cmax | 84 days | Maximum serum concentration of dengushield |
Countries
Australia
Outcome results
None listed